Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | January 20, 2026 | January 21, 2026 |
| Adverum Biotechnologies, Inc.ADVM · Entity 71889 | Director | June 23, 2020 | June 25, 2020 |
| Arcus Biosciences, Inc.RCUS · Entity 4104 | See Remarks | March 25, 2019 | March 25, 2019 |
| BioAge Labs, Inc.BIOA · Entity 5569 | Director | June 10, 2026 | June 12, 2026 |
| Jiya Acquisition Corp.JYAC · Entity 123583 | Director · Chief Executive Officer | November 18, 2020 | November 19, 2020 |
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Director | June 03, 2026 | June 05, 2026 |
| MAXCYTE, INC.MXCT · Entity 6608 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date January 20, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2036-01-19 | Direct | 40,400 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 40,400 · Balance 40,400 F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.
Adverum Biotechnologies, Inc.
Report date June 23, 2020 · Filed June 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.64 · Expires 2030-06-22 | Direct | 30,000 |
Reported balance
After 2020-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-23 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest on the earlier of June 23, 2021 or the 2021 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 23, 2021 or the 2021 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.
Arcus Biosciences, Inc.
Report date March 25, 2019 · Filed March 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.23 · Expires 2029-03-24 | Direct | 400,000 |
Reported balance
After 2019-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-25 · Grant · Acquired 400,000 · Balance 400,000 F1: The option is exercisable in 48 equal monthly installments after March 25, 2019, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is exercisable in 48 equal monthly installments after March 25, 2019, subject to the Reporting Person's continued service to the Company.
BioAge Labs, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 · Expires 2036-06-09 | Direct | 22,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 22,000 · Balance 22,000 F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
Jiya Acquisition Corp.
Report date November 18, 2020 · Filed November 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Reporting Person holds 200,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: The Class B Shares held by the Reporting Person will vest as follows: 25% of the Class B Shares will vest on November 16, 2021 (the first anniversary of the transfer date), and the remaining 75% will thereafter vest in thirty-six (36) equal monthly installments, subject generally to continued employment with the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person holds 200,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.
F2: The Class B Shares held by the Reporting Person will vest as follows: 25% of the Class B Shares will vest on November 16, 2021 (the first anniversary of the transfer date), and the remaining 75% will thereafter vest in thirty-six (36) equal monthly installments, subject generally to continued employment with the Issuer through each such date.
LB PHARMACEUTICALS INC
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.95 · Expires 2036-06-02 | Direct | 10,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 10,000 · Balance 10,000 F1: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
MAXCYTE, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,314 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 70,314 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16 | Direct | 49,579 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579 F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aravive, Inc.
Report date April 08, 2020 · Filed April 09, 2020
Section 16 reporting ended · disclosed 2020-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,250 |
Reported balance
After 2020-04-08 transaction · row 1
1 source rowRow 1 · 2020-04-08 · Disposition to issuer · Disposed 42,750 · Balance 14,250 F1: The reporting person resigned her positions as President, Chief Executive Officer and member of the Board of Directors of Aravive, Inc. on April 8, 2020, resulting in the forfeiture of 42,750 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on January 9, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person resigned her positions as President, Chief Executive Officer and member of the Board of Directors of Aravive, Inc. on April 8, 2020, resulting in the forfeiture of 42,750 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on January 9, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:28 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 49,579 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000905148-26-003055 · form4.xml · derivative · entry 2 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,579 Underlying: Common Stock · 49,579 shares Expires 2036-06-16 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:28 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 30,421 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003055 · form4.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,314 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:35 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.48 | $0.00 |
DisclosureSEC source: 0001771213-26-000004 · form4-06122026_080642.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $27.95 | $0.00 |
DisclosureSEC source: 0001771213-26-000002 · form4-06052026_090613.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 40,400 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001193125-26-018021 · ownership.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 40,400 shares Expires 2036-01-19 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 22,449 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-25-024452 · form4-09122025_060919.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,449 Underlying: Common Stock · 22,449 shares Expires 2035-09-09 F1 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 25, 2025 Filed Aug 27, 2025 21:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 10,684 | $2.09 | $22,377.64 |
DisclosureSEC source: 0000905148-25-003155 · form4.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,893 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2025. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.07 to $2.1212, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 50,790 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000905148-25-002234 · form4.xml · derivative · entry 2 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,790 Underlying: Common Stock · 50,790 shares Expires 2035-06-17 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 29,210 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002234 · form4.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,577 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:47 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001415889-25-016296 · form4-06092025_080617.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:32 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 40,400 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-001983 · form4-01232025_110145.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 40,400 shares Expires 2035-01-20 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments beginning on February 21, 2025. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:17 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 30,000 | $1.55 | $46,404.00 |
DisclosureSEC source: 0001415889-24-028247 · form4-12042024_091224.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.515 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 27, 2024 Filed Mar 10, 2025 20:11 UTC Amendment | BioAge Labs, Inc. BIOA · Entity 5569 | PurchaseCommon Stock | 3,000 | $18.00 | $54,000.00 |
DisclosureSEC source: 0001415889-25-007506 · form4a-03102025_080325.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 F1 · shares: The reported securities were purchased through a directed share program in connection with the Issuer's initial public offering. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:21 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024043 · form4-09272024_080911.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-09-24 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:49 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 20,200 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001415889-24-016955 · form4-06142024_080638.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,200 Underlying: Common Stock · 20,200 shares Expires 2034-06-12 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the 13th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:38 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 40,701 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001415889-24-016713 · form4-06132024_090609.xml · derivative · entry 2 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,701 Underlying: Common Stock · 40,701 shares Expires 2034-06-10 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:38 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016713 · form4-06132024_090609.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,367 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| April 17, 2024 Filed Sep 27, 2024 20:21 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 28,497 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001415889-24-024043 · form4-09272024_080911.xml · derivative · entry 2 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,497 Underlying: Common Stock · 28,497 shares Expires 2034-04-16 F2 · date: This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). F3 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-23-039471 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 22, 2024, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:43 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 20,200 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001209191-23-039096 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,200 Underlying: Common Stock · 20,200 shares Expires 2033-06-19 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 20:45 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001209191-23-020293 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-03-19 F1 · derivative.exercise_date: This grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. 23,333 of the shares underlying this option vested on March 20, 2023 and the remaining 16,667 shares will vest in 15 equal monthly installments thereafter, beginning on April 14, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 29, 2022 Filed Jul 8, 2022 20:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 26,900 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-22-041607 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,900 Underlying: Common Stock · 26,900 shares Expires 2032-06-28 F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 29, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 00:23 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 12,004 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001209191-22-037643 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,004 Underlying: Common Stock · 12,004 shares Expires 2032-06-14 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050936 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:50 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 12,004 | $0.00 Strike: $59.66 | $0.00 |
DisclosureSEC source: 0001209191-21-040725 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,004 Underlying: Common Stock · 12,004 shares Expires 2031-06-10 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 00:03 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 3,000 | $19.00 | $57,000.00 |
DisclosureSEC source: 0000899243-20-019912 · doc4.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 17:45 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $25.64 | $0.00 |
DisclosureSEC source: 0001209191-20-038959 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-22 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 23, 2021 or the 2021 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 16:10 UTC | Aravive, Inc. ARAV · Entity 114535 | Disposition to issuerCommon Stock | 42,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010591 · doc4.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 F1 · shares: The reporting person resigned her positions as President, Chief Executive Officer and member of the Board of Directors of Aravive, Inc. on April 8, 2020, resulting in the forfeiture of 42,750 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on January 9, 2020. Read SEC document |
| January 09, 2020 Filed Jan 9, 2020 19:20 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Options · Derivative | 143,000 | $0.00 Strike: $13.77 | $0.00 |
DisclosureSEC source: 0000899243-20-000907 · doc4.xml · derivative · entry 2 Hemrajani Rekha · CIK 0001771213 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Common stock · 143,000 shares Expires 2030-01-08 F2 · shares: The stock option to purchase 143,000 shares of Common Stock vests as follows: 25% of the shares vest on the one year anniversary of the date of grant and the remaining 75% of the shares vest in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Company. F2 · derivative.exercise_date: The stock option to purchase 143,000 shares of Common Stock vests as follows: 25% of the shares vest on the one year anniversary of the date of grant and the remaining 75% of the shares vest in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Company. Read SEC document |
| January 09, 2020 Filed Jan 9, 2020 19:20 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantCommon Stock | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000907 · doc4.xml · nonDerivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 F1 · shares: Represents the grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock ("Common Stock") of Aravive, Inc. (the "Company"). The RSUs vest as follows: 25% of the shares vest on each of January 9, 2021, January 9, 2022 January 9, 2023 and January 9, 2024, subject to the reporting person's continued service to the Company. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:15 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 33,750 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001209191-19-046306 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 33,750 shares Expires 2029-07-30 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (a) the 2020 annual meeting of stockholders and (b) July 31, 2020. The options were issued in connection with an amendment to the company's non-employee director compensation policy, such that the director's total annual option grants correspond to the amended policy. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:21 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001209191-19-044245 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2029-07-30 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (a) the 2020 annual meeting of stockholders and (b) July 31, 2020. Read SEC document |
| May 01, 2019 Filed May 3, 2019 16:38 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001209191-19-027395 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-04-30 F1 · derivative.exercise_date: 1/3 of the total number of shares subject to the option vest and become exercisable on each anniversary of May 1, 2019 (the "Vesting Commencement Date"), such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 22:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001209191-19-021233 · doc4.xml · derivative · entry 1 Hemrajani Rekha · CIK 0001771213 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-03-24 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after March 25, 2019, subject to the Reporting Person's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.